May 9, 2022
Aldose Reductase Inhibitor AT-007 Prevents Mitochondrial Dysfunction and Neurodegeneration in Sorbitol Dehydrogenase Deficiency-Induced Neuropathy
Presented by Yi Zhu, MD, PhD, Assistant Scientist, University of Miami; Amanda Lobato, PhD Candidate, University of Miami; Adriana Rebelo, PhD, Scientist, University of Miami; Tijana Canic, Research Laboratory Technician, University of Miami; Sheyum Syed, PhD, MS, Associate Professor, University of Miami; Riccardo Perfetti, MD, PhD, Chief Medical Officer at Applied Therapeutics; Shoshana Shendelman, PhD, CEO and Founder at Applied Therapeutics; Stephan Züchner, MD, PhD, Professor and Chair, Department of Human Genetics, University of Miami; Grace Zhai, PhD, Professor of Molecular and Cellular Pharmacology
University of Miami 2022 Annual Meeting of the Peripheral Nerve Society 

AT-007 Significantly Lowers Blood Sorbitol Levels in Patients with Hereditary Neuropathy Resulting from Sorbitol Dehydrogenase (SORD) Deficiency
Presented by Riccardo Perfetti, MD, PhD, Chief Medical Officer at Applied Therapeutics; Jahannaz Dastgir, DO, Director of Clinical Research at Applied Therapeutics; Shoshana Shendelman, PhD, CEO and Founder at Applied Therapeutics
2022 Annual Meeting of the Peripheral Nerve Society

Circulating Sorbitol Levels and Severity of Disease in Patients with Sorbitol Dehydrogenase (SORD) Deficiency
Presented by Riccardo Perfetti, MD, PhD, Chief Medical Officer at Applied Therapeutics; Shoshana Shendelman, PhD, CEO and Founder at Applied Therapeutics
2022 Annual Meeting of the Peripheral Nerve Society

Galactitol – But Not Gal-1p – Level is a Predictor of Disease Severity in Children with Classic Galactosemia on Galactose-Restricted Diet
Presented by Riccardo Perfetti, MD, PhD, Chief Medical Officer at Applied Therapeutics; Evan Bailey, MD, Executive Medical Director at Applied Therapeutics; Francesca Lawson, MD, FAHA, Vice President Clinical Regulatory Strategy at Applied Therapeutics; Stella Wang, MPH, Head Medical Projects & Data Analytics at Applied Therapeutics; Laura Saltonstall, MD, MBA, Vice President Medical Affairs, Head of Medical Strategy, Operations at Applied Therapeutics; Amanda Krumnow, PharmD, MBA, Vice President Medical Affairs at Applied Therapeutics; Shoshana Shendelman, PhD, CEO and Founder at Applied Therapeutics
43rd Annual Meeting of the Society for Inherited Metabolic Disorders

Baseline Disease Characteristics of 47 Pediatric Classic Galactosemia Patients in the ACTION-Galactosemia KIDS AT-007 Interventional Study Demonstrate the Multi-System Burden of Disease
Presented by Riccardo Perfetti, MD, PhD, Chief Medical Officer at Applied Therapeutics; Ayesha Ahmad, MBBS, Division of Pediatric Genetics, Metabolism and Genomic Medicine, University of Michigan; Han C. Phan, MD, Director of Clinical Research, Rare Disease Research LLC, Atlanta, GA; Janet Thomas, MD, Director, Inherited Metabolic Disease Clinic, University of Colorado School of Medicine and the Children’s Hospital Colorado; Francesca Lawson, MD, FAHA, Vice President Clinical Regulatory Strategy; Evan Bailey, MD, Executive Medical Director at Applied Therapeutics; Laura Saltonstall, MD, MBA, Vice President Medical Affairs, Head of Medical Strategy, Operations at Applied Therapeutics; Shoshana Shendelman, PhD, CEO and Founder at Applied Therapeutics
43rd Annual Meeting of the Society for Inherited Metabolic Disorders

November 23, 2021

Progressive Worsening of the Central Nervous System Phenotype in Children with Classic Galactosemia on Galactose Restricted Diet: A Cross-Sectional Analysis
Presented by Shoshana Shendelman, CEO and Founder of Applied Therapeutics; Riccardo Perfetti, Chief Medical Officer at Applied Therapeutics; Laura Saltonstall, VP, Medical Affairs at Applied Therapeutics
14th International Congress of Inborn Errors of Metabolism

Qualitative Interviews of Adults with Classic Galactosemia (CG) and their Caregivers: Disease Burden and Challenges with Daily Living
Presented by Shoshana Shendelman, CEO and Founder of Applied Therapeutics; Riccardo Perfetti, Chief Medical Officer at Applied Therapeutics; Laura Saltonstall, VP, Medical Affairs at Applied Therapeutics
14th International Congress of Inborn Errors of Metabolism

Galactitol Level is a Predictor of Disease Severity in Children with Classic Galactosemia on Galactose Restricted Diet
Presented by Shoshana Shendelman, CEO and Founder of Applied Therapeutics; Riccardo Perfetti, Chief Medical Officer at Applied Therapeutics; Laura Saltonstall, VP, Medical Affairs at Applied Therapeutics
14th International Congress of Inborn Errors of Metabolism

April 13, 2021

Progressive Worsening of Central Nervous System Phenotype in Children with Classic Galactosemia: a Cross-Sectional Analysis
Presented by Riccardo Perfetti, MD, PhD, Chief Medical Officer of Applied Therapeutics
2021 American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting

October 26, 2020

Positive Biomarker Efficacy Results from the ACTION-Galactosemia Study
Presented by Riccardo Perfetti, MD, PhD, Chief Medical Officer of Applied Therapeutics

Post-Natal Galactitol Reduction is Associated with Normalization of CNS Phenotype in Animal Model of Galactosemia
Presented by Riccardo Perfetti, MD, PhD, Chief Medical Officer of Applied Therapeutics
American Society of Human Genetics (ASHG) 2020 Annual Meeting

September 23, 2020

AT-001: A Next Generation Aldose Reductase Inhibitor with Improved Potency, Selectivity and Specificity Protects from Cellular Damage Associated with Hyperglycaemia
Presented by Riccardo Perfetti, MD, PhD, Chief Medical Officer of Applied Therapeutics

Addressing Safety and Specificity with Aldose Reductase Inhibition: Development of AT-001 for Diabetic Cardiomyopathy
Presented by Riccardo Perfetti, MD, PhD, Chief Medical Officer of Applied Therapeutics
56th Annual Meeting of the European Association for the Study of Diabetes (EASD)

July 17-19, 2020

AT-007: Development of an Oral Treatment for Patients with Galactosemia
Presented by Shoshana Shendelman, PhD, CEO and Founder, Applied Therapeutics
Galactosemia Foundation Conference

ACTION-Galactosemia: Clinical Experience with Adult Galactosemia Patients and Path Forward
Presented by Riccardo Perfetti, MD, PhD, Chief Medical Officer, Applied Therapeutics
Galactosemia Foundation Conference

ACTION-Galactosemia Kids: Pediatric Study of AT-007 in Children with Galactosemia
Presented by Shoshana Shendelman, PhD, CEO and Founder, Applied Therapeutics
Galactosemia Foundation Conference

April 28, 2020
 
Applied Therapeutics Galactosemia Educational Symposium
Presented by Dr. Shoshana Shendelman, PhD & Dr. Riccardo Perfetti, MD, PhD
Moderated by Dr. Eva-Kozicz, MD, PhD

December 5-7, 2019

The ARISE-HF Study — Development of AT-001 for the Treatment of Diabetic Cardiomyopathy: Rationale and Study Design
Presented by Dr. James Januzzi, MD

 
16th Global Cardio Vascular Clinical Trialists (CVCT) Forum
Washington, D.C.

November 16-18, 2019

Clinical Assessment of AT-001, an Aldose Reductase Inhibitor in Development for Diabetic Cardiomyopathy: a 28 Day Proof of Concept Study (poster)

Clinical Assessment of AT-001, an Aldose Reductase Inhibitor in Development for Diabetic Cardiomyopathy: a 28 Day Proof of Concept Study (presentation – please download and view in Slideshow mode to hear presentation)

American Heart Association (AHA) Scientific Session 2019
Philadelphia, Pennsylvania

American Society of Human Genetics (ASHG) 2019 Annual Meeting
Houston, Texas

September 16-20, 2019

AT‑001 Significantly Reduces Cardiac Damage in an Animal Model of Diabetic Cardiomyopathy

55th Annual Meeting of the European Association for the Study of Diabetes (EASD)
Barcelona, Spain

September 13-16, 2019

Preclinical and Clinical Proof of Concept for Metabolic Intervention in Diabetic Cardiomyopathy

Heart Failure Society of America (HFSA) 23rd Annual Scientific Meeting
Philadelphia, PA

October 15-16, 2018

A Novel Investigational Treatment In Preclinical Development For Galactosemia

NORD Rare Summit 2018
Washington, D.C.

AT-007-1005 Clinical Study

Please fill out the form below to view information about AT-007, e.g. a list of contraindicated medications.
Name(Required)